AstraZeneca Dirección

Dirección controles de criterios 3/4

El CEO de AstraZeneca es Pascal Soriot , nombrado en Oct 2012, tiene una permanencia de 12.08 años. compensación anual total es $21.48M, compuesta por 8.5% salario y 91.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.014% de las acciones de la empresa, por valor de ARS29.80B. La antigüedad media del equipo directivo y de la junta directiva es de 9.4 años y 7 años, respectivamente.

Información clave

Pascal Soriot

Chief Executive Officer (CEO)

US$21.5m

Compensación total

Porcentaje del salario del CEO	8.5%
Permanencia del CEO	12.1yrs
Participación del CEO	0.01%
Permanencia media de la dirección	9.4yrs
Promedio de permanencia en la Junta Directiva	7yrs

Actualizaciones recientes de la dirección

No hay actualizaciones

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Pascal Soriot en comparación con los beneficios de AstraZeneca?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$6b
Jun 30 2024	n/a	n/a	US$6b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$21m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$5b
Dec 31 2022	US$18m	US$2m	US$3b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	-US$1b
Mar 31 2022	n/a	n/a	-US$1b
Dec 31 2021	US$21m	US$2m	US$112m
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$22m	US$2m	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$20m	US$2m	US$1b
Sep 30 2019	n/a	n/a	US$2b
Jun 30 2019	n/a	n/a	US$2b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$16m	US$2m	US$2b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$3b
Mar 31 2018	n/a	n/a	US$3b
Dec 31 2017	US$14m	US$2m	US$3b

Compensación vs. Mercado: La compensación total de Pascal($USD21.48M) está por encima de la media de empresas de tamaño similar en el mercado AR ($USD5.72M).

Compensación vs. Ingresos: La compensación de Pascal ha sido consistente con los resultados de la empresa en el último año.

CEO

Pascal Soriot (65 yo)

12.1yrs

Permanencia

US$21,484,390

Compensación

Mr. Pascal Soriot, M.B.A., D.V.M., has been the Chief Executive Officer and Executive Director at AstraZeneca PLC since October 1, 2012. He served as Director at Acerta Pharma B.V. He had been Independent...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Pascal Soriot	CEO & Executive Director	12.1yrs	US$21.48m	0.014% ARS 29.8b
Aradhana Sarin	CFO & Executive Director	3.3yrs	US$5.62m	0.0053% ARS 11.1b
Pam Cheng	EVP of Global opt. & IT	9.4yrs	sin datos	sin datos
Andrew Barnett	Head of Investor Relations	no data	sin datos	sin datos
Jeffrey Pott	CHRO, Chief Compliance Officer	15.8yrs	sin datos	sin datos
Gonzalo Vina	Head of Global Media Relations	no data	sin datos	sin datos
Ruud Dobber	Executive Vice-President of BioPharmaceuticals Business Unit	11.8yrs	sin datos	sin datos
Susan Galbraith	Executive Vice President of Oncology Research & Development	no data	sin datos	sin datos
Leon Wang	Executive VP of International & China President	10.8yrs	sin datos	sin datos
Iskra Reic	Executive Vice-President of Vaccines & Immune Therapies	7.6yrs	sin datos	sin datos
David Fredrickson	Executive Vice-President of Oncology Business Unit	7.1yrs	sin datos	sin datos
Ruth March	Senior VP of Precision Medicine - R&D Oncology	5.8yrs	sin datos	sin datos

9.4yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AZN es experimentado (9.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Pascal Soriot	CEO & Executive Director	12.1yrs	US$21.48m	0.014% ARS 29.8b
Aradhana Sarin	CFO & Executive Director	3.3yrs	US$5.62m	0.0053% ARS 11.1b
Pam Cheng	EVP of Global opt. & IT	no data	sin datos	sin datos
Jeffrey Pott	CHRO, Chief Compliance Officer	no data	sin datos	sin datos
Marcus Wallenberg	Non-Executive Director	25.6yrs	US$159.35k	0.0039% ARS 8.1b
Philip John Broadley	Senior Independent Non-Executive Director	7.6yrs	US$254.96k	0.00052% ARS 1.1b
Michel Demare	Independent Chairman	5.2yrs	US$744.49k	0.00065% ARS 1.4b
Deborah DiSanzo Eldracher	Independent Non-Executive Director	6.9yrs	US$152.98k	0.000060% ARS 125.2m
Sherilyn S. McCoy	Independent Non-Executive Director	7.1yrs	US$223.09k	0.00011% ARS 229.5m
Euan Ashley	Independent Non-Executive Director	4.1yrs	US$151.70k	0.000070% ARS 146.1m
Shu Kam Mok	Independent Non-Executive Director	5.8yrs	US$140.23k	0.00013% ARS 271.3m
Nazneen Rahman	Independent Non-Executive Director	7.4yrs	US$203.97k	0.000070% ARS 146.1m

7.0yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de AZN se considera experimentada (7 años de antigüedad promedio).

AstraZeneca Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Recent updates

AstraZeneca PLC Announces Positive High-Level Results from the Capitello-281 Phase III Trial

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca plc Announces Astrazeneca and Ionis' Wainzua (Eplontersen) Recommendation for Approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

Astrazeneca’S CALQUENCE® (acalabrutinib) Receives Priority Review in the US for Patients with Untreated Mantle Cell Lymphoma

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Cas Datifan in Combination with Volrustomig in Renal Cell Carcinoma

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Astrazeneca PLC Tagrisso Receives US Approval in Unresectable Stage III EGFR-Mutated Lung Cancer Lung Cancer

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

AstraZeneca PLC’s FluMist Receives Approval for Self-Administration in the US

AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca Announces Positive Results from the Niagara Phase III Trial

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Astrazeneca Presents Interim Results from the Randomized NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Present At the WCLC 2024

Astrazeneca's Imfinzi Receives Approval in US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery

Astrazeneca's Supplemental Biologics License Application for Imfinzi (Durvalumab) Granted Priority Review and Breakthrough Therapy Designation for Patients with Limited-Stage Small Cell Lung Cancer in the US

Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial

FDA Advisory Committee Reviewes Astrazeneca's Imfinzi for Treatment of Resectable Non-Small Cell Lung Cancer Based on Aegean Phase III Trial Results

Astrazeneca plc Announces Voydeya Approved in Canada as Add-On Therapy to Ravulizumab or Eculizumab for Adults with the Rare Disease PNH Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad